9,570 Shares in Zoetis Inc. (NYSE:ZTS) Acquired by Dynamic Technology Lab Private Ltd

Dynamic Technology Lab Private Ltd purchased a new stake in Zoetis Inc. (NYSE:ZTS - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 9,570 shares of the company's stock, valued at approximately $1,559,000.

A number of other large investors have also added to or reduced their stakes in the stock. Pilgrim Partners Asia Pte Ltd bought a new position in shares of Zoetis in the fourth quarter worth $59,000. Resona Asset Management Co. Ltd. bought a new position in Zoetis in the 4th quarter valued at about $56,032,000. Wealth Advisors of Tampa Bay LLC bought a new stake in shares of Zoetis during the 4th quarter worth approximately $1,587,000. Prudential PLC lifted its holdings in shares of Zoetis by 12.1% during the 4th quarter. Prudential PLC now owns 151,546 shares of the company's stock worth $24,691,000 after acquiring an additional 16,327 shares during the period. Finally, Landscape Capital Management L.L.C. boosted its position in shares of Zoetis by 419.1% during the 4th quarter. Landscape Capital Management L.L.C. now owns 12,157 shares of the company's stock worth $1,981,000 after acquiring an additional 9,815 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Trading Down 5.2 %

Shares of ZTS stock traded down $8.06 during trading hours on Thursday, hitting $145.49. 1,886,864 shares of the company's stock traded hands, compared to its average volume of 2,615,944. The stock has a market cap of $65.15 billion, a PE ratio of 26.62, a price-to-earnings-growth ratio of 2.78 and a beta of 0.92. The stock's 50 day simple moving average is $163.46 and its 200 day simple moving average is $172.01. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a 12 month low of $139.70 and a 12 month high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping the consensus estimate of $1.37 by $0.03. The firm had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. On average, sell-side analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.37%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis's dividend payout ratio is presently 36.56%.

Analyst Upgrades and Downgrades

Several research analysts have commented on ZTS shares. Barclays boosted their price objective on shares of Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research report on Friday, February 14th. StockNews.com raised Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. Stifel Nicolaus reduced their price objective on Zoetis from $210.00 to $180.00 and set a "buy" rating on the stock in a research note on Tuesday, January 7th. Piper Sandler boosted their target price on Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a research note on Thursday, February 27th. Finally, Morgan Stanley decreased their price target on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a report on Friday, February 14th. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Zoetis has a consensus rating of "Buy" and a consensus target price of $215.90.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the sale, the executive vice president now directly owns 16,107 shares in the company, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Willie M. Reed sold 1,210 shares of the firm's stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the sale, the director now directly owns 11,245 shares of the company's stock, valued at approximately $1,868,244.30. This trade represents a 9.71 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,862 shares of company stock worth $312,254. 0.16% of the stock is currently owned by insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.